36 results on '"Nodzon, Lisa"'
Search Results
2. Long-term follow up of the combination of ofatumumab, high-dose methylprednisolone, and lenalidomide for untreated chronic lymphocytic leukemia with biomarker analysis
3. Side-effects profile and outcomes of ponatinib in the treatment of chronic myeloid leukemia
4. A phase I clinical trial of ruxolitinib in combination with nilotinib in chronic myeloid leukemia patients with molecular evidence of disease
5. Results of a phase II study of lenalidomide and rituximab for refractory/relapsed chronic lymphocytic leukemia
6. Treatment Free Remission in Patients with Chronic Phase CML: A Single Center Experience
7. Incidence of Pleural Effusion with Dasatinib and the Effect of Switching Therapy to Bosutinib in Patients with Chronic Phase CML
8. Poster: MPN-391: A Review of Gender Differences in Quality of Life for Hematologic Malignancies
9. MPN-391: A Review of Gender Differences in Quality of Life for Hematologic Malignancies
10. Phase II study of pegylated liposomal doxorubicin, low-dose dexamethasone, and lenalidomide in patients with newly diagnosed multiple myeloma
11. Cardiovascular Adverse Events and Mitigation Strategies for Chronic Myeloid Leukemia Patients Receiving Tyrosine Kinase Inhibitor Therapy.
12. CLL-322: A Systematic Review of Quality of Life in Chronic Lymphocytic Leukemia Patients throughout the Disease Continuum
13. Venetoclax in Relapsed/Refractory Chronic Lymphocytic Leukemia: A Retrospective, Single-Institution Analysis Based on Risk Features and Debulking Strategy with Anti-CD20 Monoclonal Antibody
14. A Phase II Trial of Ibrutinib and PD-1 Blockade in Asymptomatic High Risk Chronic Lymphocytic Leukemia to Improve Immune Function
15. Conventional Real Time Quantitative Polymerase Chain Reaction Method Yields Similar Level of Sensitivity to Digital Droplet Polymerase Chain Reaction for Detection of BCR-ABL p210 Transcripts in Patients with Chronic Phase Chronic Myeloid Leukemia
16. Yeast Two‐Hybrid Technology
17. The ubiquitin ligase XBAT32 regulates lateral root development in Arabidopsis
18. 08 / Caring for Patients With Chronic Myeloid Leukemia (CML) Receiving Tyrosine Kinase Inhibitor (TKI) Therapy in an Era of Evolving Treatment Goals
19. A Systematic Review of Cardiovascular Adverse Events in Chronic Myeloid Leukemia Patients Receiving Tyrosine Kinase Inhibitor Therapy and Mitigation Strategies
20. T315I-mutated myeloid sarcoma
21. Long-Term Follow up of Front-Line Therapy with Ofatumumab, High Dose Methylprednisolone and Lenalidomide (HiLO trial) for Treatment-Naïve Chronic Lymphocytic Leukemia
22. Caring for Patients with Chronic Myeloid Leukemia (CML) Receiving Tyrosine Kinase Inhibitor (TKI) Therapy in an Era of Evolving Treatment Goals
23. Association between immunoglobulin heavy-chain variable region mutational status and isolated favorable baseline genomic aberrations in chronic lymphocytic leukemia
24. Mutational Landscape of Chronic Lymphocytic Leukemia Using Next Generation Sequencing Technologies in the Real World Clinical Setting
25. A Phase I Study of Ruxolitinib Plus Nilotinib in Chronic Phase CML Patients with Molecular Evidence of Disease
26. Sequencing Therapies in Indolent Lymphomas.
27. Minimal Residual Disease in Chronic Lymphocytic Leukemia: Highlights From SOHO 2020.
28. Clinical Characteristics, Treatment Strategies, and Outcomes for CLL Patients with BTK Mutation; A Single Center Study
29. Sequential Therapy with Ofatumumab, High Dose Methylprednisolone and Lenalidomide Is a Safe and Effective Regimen for the Treatment of Previously Treated and Untreated CLL/SLL: The Hilo Trial
30. Outcomes of Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia after Ibrutinib Discontinuation Outside Clinical Trials: A Single Institution Experience
31. Association between immunoglobulin heavy-chain variable region mutational status and isolated favorable baseline genomic aberrations in chronic lymphocytic leukemia.
32. Risk-Adapted Treatment Strategies for Chronic Lymphocytic Leukemia.
33. Supporting Adherence to Tyrosine Kinase Inhibitor (TKI) Therapy Among Patients with Chronic Myeloid Leukemia (CML)
34. An Integrative Review of Sex Differences in Quality of Life and Symptoms Among Survivors of Hematologic Malignancies.
35. Updates on Therapeutic Advancements in Relapsed or Refractory Multiple Myeloma: Highlights From SOHO 2020.
36. Emerging Therapies in Myelofibrosis: Highlights From SOHO 2020.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.